deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06829329

Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

A Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With CHB

Sponsor: Ausper Biopharma Co., Ltd.

Conditions Chronic Hepatitis B
Interventions AHB-137 NAs Placebo
Updated 2 times since 2025 Last updated: Sep 22, 2025 Started: Dec 13, 2024 Primary completion: Oct 21, 2025 Completion: Nov 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Hepatitis B and is currently ongoing. Ausper Biopharma Co., Ltd. leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Mar 2025 – ~Oct 2025 · 7 months · monthly snapshotRecruiting~Oct 2025 – present · 9 months · monthly snapshotActive Not Recruiting

Change History

2 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Mar 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ausper Biopharma Co., Ltd.
Data source: Ausper Biopharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations